NMN supplementation significantly increases NAD+ levels in postmenopausal women, improving muscle insulin sensitivity and energy markers, published in Science.
This pioneering study by Yoshino et al. (2021), published in Science, one of the most prestigious journals in the world, is the first randomized scientific trial to demonstrate in humans that oral supplementation with NMN (nicotinamide mononucleotide) significantly increases NAD+ levels in muscle tissue.
NAD+ (nicotinamide adenine dinucleotide) is a fundamental coenzyme present in all living cells, central to energy metabolism, DNA repair and the regulation of sirtuins, proteins linked to longevity. Its levels decline by 40 to 60% between ages 20 and 60.
This trial represents a decisive human proof of concept after years of promising results in animal models, paving the way for targeted supplementation strategies to counteract age-related energy decline.
25 post-menopausal women, overweight or obese (BMI 25-35), with prediabetes (elevated fasting glucose or HbA1c). Randomization 1:1 between NMN group (n=13) and placebo group (n=12). Study conducted at Washington University School of Medicine (St. Louis).
NMN supplementation 250 mg/day (MIB-626 formulation) or identical placebo for 10 weeks. Daily oral intake in the morning. Pre-post measures: euglycemic-hyperinsulinemic clamp to evaluate insulin sensitivity, muscle biopsy for molecular analysis.
Muscle insulin sensitivity (hyperinsulinemic-euglycemic clamp, gold standard). Insulin signaling in skeletal muscle (Akt phosphorylation, AS160). Expression of muscle remodeling genes (notably PDGFR-β). Safety: liver enzymes, kidney function, hematological parameters.
Dose-dependent multicenter double-blind trial (Geroscience, PMID 36482258): 80 adults aged 40-65, NMN 300/600/900 mg/day for 60 days. Confirmation of safety up to 900 mg/day. Optimal dose: 600 mg/day. Significant increase in blood NAD+ at 30 and 60 days.
This study published in Science marks a turning point in preventive aging medicine. For the first time in humans, it is demonstrated that simple oral supplementation can significantly raise NAD+ levels in target tissues, translating concretely into an improvement in energy metabolism comparable to that observed with regular physical exercise.
The 25% improvement in muscle insulin sensitivity is particularly important for our patients aged 45+: muscle insulin resistance is one of the first signs of metabolic aging, preceding type 2 diabetes by several decades. By correcting it via the restoration of NAD+, we act on a fundamental mechanism of aging, not on a symptom.
Activation of SIRT1 and PGC-1α is the signal that NMN does not just "fill" the NAD+ reservoir, it activates a cascade of cellular maintenance processes: DNA repair, mitochondrial biogenesis, epigenetic regulation. These mechanisms are at the heart of our regenerative medicine approach.
We integrate NMN into our micronutrition protocols after a complete biological assessment (NAD+ measurement, metabolic panel, epigenetic biological age) to personalize dosage and optimize efficacy according to each patient's profile.